Donor‐Derived Anti‐CD33 CAR T Cell Therapy (VCAR33) in Patients with Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant. This evidence concerns the gene CD33 and acute myeloid leukemia.